Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models

Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

(2013) Yanguang Cao et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Antibody biodistribution coefficients

(2013) Dhaval K. Shah et al.   mAbs

Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn

(2012) Yang Chen et al.   AAPS Journal

Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

(2012) Hannah M. Jones et al.   AAPS Journal

Pharmacokinetic Models for FcRn-Mediated IgG Disposition

(2012) Jim J. Xiao   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling

(2012) Ben-Fillippo Krippendorff et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

(2011) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models

(2010) Sabine Pilari et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus

(2009) Paweł Wiczling et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

(2009) Shweta R. Urva et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis

(2009) Ben-Fillippo Krippendorff et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

(2009) Hans Peter Grimm   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice

(2009) Héctor Pérez Montoyo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

(2008) Nathanae L. Dirks et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs

(2007) Jasmine P. Davda et al.   INTERNATIONAL IMMUNOPHARMACOLOGY